Inflammation in renal atherosclerotic disease

References

• Bloch M, Basile J. Clinical insights into the diagnosis and management of renovascular disease. Minerva Med.95, 357–373 (2004).
   PubMedGoogle Scholar
• Bloch M, Basile J. Clinical insights into the diagnosis and management of atherosclerotic renal disease. Curr. Atheroscler. Rep.8, 412–420 (2006).
   PubMedGoogle Scholar
• Dieter RS, Schmidt WS, Pacanowski JP, Jaff MR. Renovascular hypertension. Expert Rev. Cardiovasc. Ther.3(3), 413–422 (2005).
   PubMedGoogle Scholar
• Meier P, Rossert J, Plouin P, Bumier M. Atherosclerotic renovascular disease: beyond the renal artery stenosis. Nephrol. Dial. Transplant.22, 1002–1006 (2007).
   PubMedGoogle Scholar
• Vaziri N, Liang K, Ding Y. Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int.56, 1492–1498 (1999).
   PubMed Web of Science ®Google Scholar
• Schnackenberg C. Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am. J. Physiol. Regulatory Integrative Comp. Physiol.282, R335–R342 (2002).
   Google Scholar
• Lai EY, Patzak A, Steege A et al. Contribution of adenosine receptors in the control of arteriolar tone and adenosine–Angiotensin II interaction. Kidney Int.70, 690–698 (2006).
   PubMedGoogle Scholar
• Eberhart W, Pfeilschifter J. Nitric oxide and vascular remodeling: spotlight on the kidney. Kidney Int.72, S9–S16 (2007).
   Google Scholar
• Binder CJ, Weiher H, Exner M, Kerjaschki D. Glomerular overproduction of oxygen radicals in mpv 17 gene-inactivated mice causes podocyte foot process flattening and proteinuria. Am. J. Pathol.154, 1067–1075 (1999).
   PubMedGoogle Scholar
• Greiber S, Müller B, Daemisch P, Pavenstädt H. Reactive oxygen species alter gene expression in podocytes: induction of granulocyte macrophage-colony-stimulating factor. J. Am. Soc. Nephrol.13, 86–95 (2002).
   PubMedGoogle Scholar
• Zoja C, Abbate M, Remuzzi G. Progression of chronic kidney disease: insights from animal models. Curr. Opin. Nephrol. Hypertens.15, 250–257 (2006).
   PubMed Web of Science ®Google Scholar
• Olin J. Renal artery disease. Cardiol. Clin.20, 547–562 (2002).
   PubMedGoogle Scholar
• Camici M. Urinary detection of podocyte injury. Biomed. Pharmacother.61, 245–249 (2007).
   PubMed Web of Science ®Google Scholar
• Pätäri A, Forsblom C, Havana M et al. Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes52, 2969–2974 (2003).
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Fried LF, Cushman M et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA293, 1737–1745 (2005).
   PubMed Web of Science ®Google Scholar
• Chonchol M, Linas S. Diagnosis and management of ischemic nephropathy. Clin. J. Am. Soc. Nephrol.1, 172–181 (2006).
   PubMedGoogle Scholar
• Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double blind, placebo-controlled study on the effect of the aldosterone receptor antagonist sprionolactone in patients who have persistent proteinuria and are on long-term Angiotensin-converting enzyme inhibitor therapy, with or without an Angiotensin II receptor blocker. Clin. J. Am. Soc. Nephrol.1, 256–262 (2006).
   PubMed Web of Science ®Google Scholar
• Praga M. Therapeutic measures in proteinuric nephropathy. Kidney Int.68, S137–S141 (2005).
   Google Scholar
• Chade A, Zhu X, Mushin O. Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J.20, 1706–1708 (2006).
   PubMed Web of Science ®Google Scholar
• Lecian D, Demova H, Lodererova A et al. Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. Kidney Blood Press. Res.29, 135–143 (2006).
   PubMed Web of Science ®Google Scholar
• Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J. Am. Soc. Nephrol.17, 2006–2016 (2006).
   PubMed Web of Science ®Google Scholar
• Douglas K, O’Malley P, Jackson J. Meta-analysis: the effect of statins on proteinuria. Ann. Intern. Med.145, 117–124 (2006).
   PubMed Web of Science ®Google Scholar
• Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R. Safety considerations for statins. Curr. Opin. Lipidol.13, 637–644 (2002).
   PubMed Web of Science ®Google Scholar
• Waters DD. Safety of high-dose atorvastatin therapy. Am. J. Cardiol.96, 69–75 (2005).
   PubMedGoogle Scholar
• Wiviott SD, Cannon CP. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr. Opin. Lipidol.17, 626–630 (2006).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Hunninghake DB, Stein EA et al. Safety of rosuvastatin. Am. J. Cardiol.94, 882–888 (2004).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Iturbe B, Ferrebuz A, Vanegas V et al. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney Int.68, 2131–2142 (2005).
   PubMed Web of Science ®Google Scholar
• Rajaram V and Joseph J. Role of adenosine antagonism in the cardio-renal syndrome: pathophysiology and therapeutic potential. Curr. Heart Fail. Rep.153–157 (2007).
   PubMedGoogle Scholar
• Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC. The effects of kw-3902, an adenosine a1 receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J. Am. Coll. Cardiol.50, 1551–1560 (2007).
   PubMed Web of Science ®Google Scholar
• Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal decline in patients with focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol.2, 906–913 (2007).
   PubMed Web of Science ®Google Scholar
• Lin J, Lin-Tan D, Hsu K, Yu C. Environmental lead exposure and progression of chronic renal disease in patients without diabetes. New Engl. J. Med.348, 277–286 (2003).
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Shah SV. Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease. Curr. Opin. Nephrol. Hypetens.17, 143–148 (2008).
   PubMedGoogle Scholar
• Cheung C, Patel A, Shaheen N et al. The effect of statins on the progression of atherosclerotic renovascular disease. Nephron. Clin. Pract.107, c35–c42 (2007).
   Google Scholar